| REVIEW ARTICLE |
|
| Year : 2023 | Volume
: 14
| Issue : 1 | Page : 81 |
|
|
The prevalence of inflammatory bowel disease (IBD) in patients with multiple sclerosis (MS): A systematic review and meta-analysis
Amirreza Nasirzadeh1, Reza Jahanshahi2, Mahsa Ghajarzadeh3, Aida Mohammadi4, Abdorreza Naser Moghadasi3
1 Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran
2 Department of Neurology, University of Medical Sciences, Gorgan, Iran
3 Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
4 Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran
Correspondence Address:
Abdorreza Naser Moghadasi
Sina Hospital, Tehran
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijpvm.ijpvm_44_22
|
|
|
Background: This systematic review and meta-analysis aim to update the pooled prevalence of Inflammatory bowel disease (IBD) in patients with multiple sclerosis (MS). Methods: Two researchers independently and systematically searched PubMed, Scopus, EMBASE, Web of Science, and google scholar. They also searched for references of the included studies, and conference abstracts that were published up to September 2021. Results: The literature search revealed 5719 articles, after deleting duplicates 3616 remained. Finally, 17 studies were included. The pooled prevalence of IBD in MS was 1% (I2 = 96.3%, P < 0.001). The pooled odds ratio of developing IBD in MS cases was 1.36 (95% CI: 1.1–1.6) (I2 = 58.3, P = 0.01). Conclusions: The results of this systematic review and meta-analysis show that the pooled prevalence of IBD in MS patients was 1% and the pooled odds ratio of developing IBD in MS cases was 1.36.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
